A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

Understanding how cells turn genes on and off is one of biology's most enduring mysteries. Now, a new technology developed by ...

CRISPR has the power to correct genetic mutations, but current delivery methods are either unsafe or inefficient, keeping the technology from reaching its full medical potential. With the power to ...

In many cells of the human body, hair-like protrusions known as cilia act as antennae, allowing cells to receive signals from ...

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) ...

“While recent single-cell multiomics studies and CRISPR screens in murine NK cells have expanded our understanding, actionable genomic targets in primary human NK cells have remained largely ...

Researchers at Memorial Sloan Kettering Cancer Center (MSK) have developed some of the first robust laboratory models of a ...

A live webcast of the presentation will be accessible via Caribou’s website on the Events page. The archived webcast will be available on the Caribou website for 30 days after the event. About ...

Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will participate in the following investor conferences: ...